Navigation Links
Pharmaceutical Market & Biotechnology Industry 2013 Outlook in New Research Reports at ReportsnReports.com
Date:2/8/2013

DALLAS, Feb. 8. 2013 /PRNewswire-iReach/ -- "Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma" released by MP Advisors and available with ReportsnReports.com provides analyses of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas where new innovation will create leadership, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry.

Key Topics Covered

  • Value Based Pricing- Strength of Innovation Vs Fiscal Pressures
  • Major therapy areas to shape up pharma business going forward
  • Europe – Regulatory Pressures and Increasing Pro Generic Stance
  • Will US fall to Pricing Pressures?
  • Emerging Markets and their importance in Growth of Large Cap Pharma
  • Global Pharma -Drugs Losing Patent Protection By 2017
  • Impact of patent expiry in w.r.t. 2012 total revenue thru 2017
  • Global Pharma Research Pipeline (PhII And PhIII)- 2013
  • Global Pharma Milestones in 2013
  • Roche: Breast Cancer Franchise And Actemra To Drive Near Term Growth, And Multiple Blockbusters In Pipeline To Take Care Of Long Term Growth
  • GlaxoSmithKline: Next Generation Bronchodilators, Melanoma, Hiv And Emerging Market To Lead The Way While Regulatory Overhang In Respiratory And EU Pricing Pressure Persist
  • Bristol- Myers Squibb : Pressures To Dominate In The Near Term, Pipeline Will Take Longer To Deliver
  • AstraZeneca: 2013 Will Be A Transition Year And AZN May Have To Take Some Bold Initiatives
  • Eli Lilly: Late Stage Pipeline Fickle And Risky
  • Merck: News-flow from Mega-trial on MRK's cardiology Franchise would reshape Merck's Growth Prospects
  • Novartis: Back on a Growth Trajectory
  • Novo Nordisk: Hemophilia Franchise and Thrice Weekly Degludec – The Future Drivers
  • Pfizer: M&A Only Can Drive Further Upside In The Near Term
  • Sanofi: Solid Base Business, But Upside From Pipeline Will Take Longer To Come About
  • Global Pharma Sector Industry Tables

Profitable Biotech (Mature Biotech) and non-Profitable Biotech companies (Rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and Market Cap match the large global pharma. Dividend and consolidation could be the future drivers and continue to attract long term investors. Optimism prevails around the future of this sector as a whole which was reflected in the unprecedented rally in shares in 2012. We expect this trend to continue in the next five year driven by launch of Innovative drugs catering to unmet needs in Alzheimer's, HCV, osteoporosis, RA, Psoriasis, MS, Dyslipidemia, Cystic fibrosis, Cancer and orphan diseases. Drug approvals and label expansion of existing portfolio of launched drugs and data from late stage pipeline drugs should maintain the growth momentum and investors interest.

"Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech" sector report provides valuations and an in depth analyses of biotech companies, their launched drug portfolio and promising drug candidates in the pipeline. The report discusses the competitive landscape of the targeted therapy areas and the innovative strategy each company is deploying to create or retain its leadership in the therapy areas. Forecast for major marketed drugs and drugs in the pipeline are included after factoring, competition, and risks from changing regulatory environment which could change the future market dynamics. Risk reward analyses of important upcoming milestones of the companies are included which should help fund managers as well as pharma company management to make critical decisions.

The New Avatar's of Microbes is a growing threat worldwide and the report "Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars" expect "GAINS" for companies focused in the anti-infective therapy class. "Pill vs. Prick"- is gaining popularity as new oral options are entering the market for RA, Psoriasis, MS etc. Pricing and experience of patients and physicians will drive compliance and define market opportunity of these drugs. Orphan disease focus will continue to remain attractive and success of Eteplirsen (PhII, Sarepta) for the treatment of Duchenne muscular dystrophy (DMD) and other antisense, RNAi drugs in the pipeline could see the final maturing of oligonucleotide based drug therapies. This research provides an in depth analyses of biotech companies and their drug pipeline amidst competition and dynamic regulatory environment.

Explore more reports on the Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/ and the Biotechnology Industry @ http://www.reportsnreports.com/market-research/biotechnology/.

About Us:

ReportsnReports.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Our repository covers company profiles and SWOT analysis reports of companies in multiple industries as well as industry profiles for geographies across the globe @ http://www.marketreportsonline.com/.



Media Contact: Priyank Tiwari ReportsnReports.com, + 1 888 391 5441, sales@reportsandreports.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE ReportsnReports.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
2. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
3. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
4. Ohr Pharmaceutical to Present at 15th Annual BIO CEO & Investor Conference
5. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
6. Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures
7. Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process
8. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
9. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
10. Optimer Pharmaceuticals to Present at Leerink Swann Global Healthcare Conference
11. KaloBios Pharmaceuticals Completes Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Daiichi ... preliminary safety and efficacy data from a phase ... MDM2 inhibitor, suggesting that DS-3032 may be a ... myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ... the phase 1 study of DS-3032 were presented in ...
(Date:12/5/2016)... -- BD (Becton, Dickinson and Company) (NYSE: BDX ... an enhanced technology platform designed with the ability to ... Pyxis™ and Alaris™ systems, at this year,s American ... being held in Las Vegas ... that approximately 68 percent of medication errors occur during ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. ... at the 2016 Annual Meeting of the American Epilepsy ... CIII, is indicated as an adjunctive therapy for the ... secondarily generalized seizures and primary generalized tonic-clonic seizures (PGTC) ... age and older. Please see Important Safety Information for ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... It can be argued that people these days ... members as they do for their human friends and family. As pets have ... highest quality and most innovative pet products has also increased. , For ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health Center ... recognizing the organization as a top behavioral service provider in the country. The ... quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured via ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, one of ... particle counting and sizing services for USP 788 and 789 particulate standards compliance. ... as a response to the needs of pharmaceutical and medical device manufacturers, who ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... Vancouver, B.C., Canada (PRWEB) , ... December 06, ... ... Consultants (STC) announce the availability of the newly updated International Audit Protocol Consortium ... world use IAPC EHS audit protocols to understand the scope of their EHS ...
Breaking Medicine News(10 mins):